RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Comprehensive characterization of the alternative splicing landscape in ovarian cancer reveals novel events associated with tumor-immune microenvironment.
Comprehensive characterization of the alternative splicing landscape in ovarian cancer reveals novel events associated with tumor-immune microenvironment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
提出的 AS 特征是一种有前景的生物标志物,可用于评估 OV 的总生存期(OS)。AS 事件特征与肿瘤免疫微环境相结合,使人们对 OV 患者的免疫状态有了更深入的了解,也为探索新的预后预测因子和精准治疗方法提供了新的见解。
卵巢癌(OV)严重威胁女性健康。免疫治疗是一种新方法。信使RNA(mRNA)的可变剪接(AS)及其调控与理解每一个癌症标志高度相关,并可能提供更广泛的靶点空间。
我们从癌症基因组图谱(TCGA)数据库下载了587个肿瘤组织的临床信息和mRNA表达谱。我们构建了一个风险评分模型来预测OV患者的预后。进一步探讨了基于AS的聚类与肿瘤免疫微环境特征之间的关联。还根据风险评分分组对每个OV样本进行了ESTIMATE算法。共筛选出三个与风险评分显著相关的免疫检查点基因。
AS事件是OV队列中可靠且稳定的独立风险预测因子。高风险评分组患者预后较差(P<0.001)。活化的肥大细胞、静息的NK细胞和中性粒细胞与风险评分呈正相关。低风险评分组中M1型巨噬细胞数量也更多(P<0.05)。检查点基因CD274、CTLA-4和PDCD1LG2与OV中AS的风险评分呈负相关。
Ovarian cancer (OV) is a serious threat to women's health. Immunotherapy is a new approach. Alternative splicing (AS) of messenger RNA (mRNA) and its regulation are highly relevant for understanding every cancer hallmark and may offer a broadened target space.
We downloaded the clinical information and mRNA expression profiles of 587 tumor tissues from The Cancer Genome Atlas (TCGA) database. We constructed a risk score model to predict the prognosis of OV patients. The association between AS-based clusters and tumor-immune microenvironment features was further explored. The ESTIMATE algorithm was also carried out on each OV sample depending on the risk score groups. A total of three immune checkpoint genes that have a significant correlation with risk scores were screened.
The AS-events were a reliable and stable independent risk predictor in the OV cohort. Patients in the high-risk score group had a poor prognosis (P<0.001). Mast cells activated, NK cells resting, and Neutrophils positively correlated with the risk score. The number of Macrophages M1 was also more numerous in the low-risk score group (P<0.05). Checkpoint genes CD274, CTLA-4, and PDCD1LG2, showed a negative correlation with the risk score of AS in OV.
The proposed AS signature is a promising biomarker for estimating overall survival (OS) in OV. The AS-events signature combined with tumor-immune microenvironment enabled a deeper understanding of the immune status of OV patients, and also provided new insights for exploring novel prognostic predictors and precise therapy methods.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。